/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
Acquisition of Assets of DOD Biotech Public Company Limited regarding the Acquisition of Land and Establishment of Subsidiary, which is Class 2 Transaction (Schedule 1) DOD Biotech Public Company Limited ( the
>คณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์
counterparty, and include terms for the future sale of SDA shares of SUSCO wherein Sinopec must be granted tag-along rights. This results in reduced flexibility and adaptability in SUSCO’s future management
DIMET (SIAM) PUBLIC COMPANY LIMITED DO DAY DREAM PUBLIC COMPANY LIMITED DOD BIOTECH PUBLIC COMPANY LIMITED DOHOME PUBLIC COMPANY LIMITED DOI KHAM FOOD PRODUCTS COMPANY LIMITED DON MUANG TOLLWAY PUBLIC
ธุรกิจใหม่ ๆ ของ SUSCO ซึ่งเงื่อนไขดังกล่าวบังคับใช้กับ SUSCO เพียงฝ่ายเดียว ไม่บังคับใช้กับคู่สัญญา และมีเงื่อนไขการขายหุ้น SDA ของ SUSCO ในอนาคต โดย Sinopec ต้องได้สิทธิในการร่วมขายหุ้น (tag-along
Assets by Subsidiary of DOD Biotech Public Company Limited for the Purchase and Acceptance of Transfer of the Entire Business of BGP Spectrum Power Co., Ltd., and Establishment of Subsidiary, Classified as
in circulation in the amount of Baht 29.50 million to be able to be used to circulate in the company. And can also be used to invest in other sub-businesses such as BSMYCO Biotech Co., Ltd., which the